TOP TEN perturbations for 40092_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40092_at
Selected probe(set): 201354_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40092_at (201354_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.8274336Number of Samples:11 / 6
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | normal ovarian surface epithelial cell sample |
| Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)
Relative Expression (log2-ratio):-1.5048046Number of Samples:7 / 8
| Experimental | precursor-B-ALL study 7 (PDX; long-term; >10wk) |
| Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis). | |
| Control | precursor-B-ALL study 7 (late relapse; >24m) |
| Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457. |
ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)
Relative Expression (log2-ratio):-1.4044266Number of Samples:22 / 11
| Experimental | ovarian tumor study 11 (high grade) |
| Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma. | |
| Control | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. |
ovarian tumor study 17 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):1.3358126Number of Samples:9 / 10
| Experimental | ovarian tumor study 17 |
| Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases. |
ovarian tumor study 11 (low grade) / ovarian tumor study 11 (borderline)
Relative Expression (log2-ratio):1.177145Number of Samples:11 / 8
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | ovarian tumor study 11 (borderline) |
| Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.107171Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
IgA nephropathy study 8 / control glomerulus tissue
Relative Expression (log2-ratio):1.0949469Number of Samples:20 / 20
| Experimental | IgA nephropathy study 8 |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures. | |
| Control | control glomerulus tissue |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):-1.062232Number of Samples:2 / 5
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; lung) |
| Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
pediatric meningococcal sepsis study 1 (24h; monocyte) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-1.0577164Number of Samples:3 / 3
| Experimental | pediatric meningococcal sepsis study 1 (24h; monocyte) |
| Monocyte (CD14+) samples obtained from blood samples of children with (suspected) meningococcal sepsis collected 24 hours after admission to the pediatric intensive care unit (PICU). Granulocytes and peripheral blood mononuclear cells (PBMCs) were isolated. From the PBMCs, CD14+ cells (monocytes) and CD14- cells (enriched for B- and T-cells) were separated using autoMACS sorting. | |
| Control | normal monocyte (CD14+) sample |
| Normal monocyte (CD14+) samples obtained from peripheral blood of healthy children admitted for elective minor non-infectious surgery or MRI. Ten ml of whole blood samples were used to perform a Ficoll density separation using Lymphoprep. Granulocytes and peripheral blood mononuclear cells (PBMCs) were isolated. From the PBMCs, CD14+ cells (monocytes) and CD14- cells (enriched for B- and T-cells) were separated using autoMACS sorting. |
precursor-B-ALL study 3 (BCR-ABL) / T-ALL study 3
Relative Expression (log2-ratio):1.0281935Number of Samples:4 / 29
| Experimental | precursor-B-ALL study 3 (BCR-ABL) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |